Pediatric Cardiology

, Volume 32, Issue 3, pp 334–341

Engineered Human Cardiac Tissue

Riley Symposium


The human heart is the first organ to develop during embryogenesis and is arguably the most essential organ for life. However, after birth, the heart has very little capacity to repair malformations such as congenital heart defects or to regenerate after an injury such as myocardial infarction. Cardiac tissue engineering addresses the need for a therapeutic biologic implant to restore cardiac structure and muscle mass. This review highlights current research in cardiac tissue engineering that uses human cardiomyocytes derived from embryonic stem cells. Other human cell sources are discussed because future human therapies will benefit from novel techniques using human-induced pluripotent stem cells and cardiomyocytes derived from direct reprogramming of somatic cells. Furthermore, this review examines the main approaches to creating engineered cardiac tissue with synthetic scaffolds, natural scaffolds, or no exogenous scaffold (i.e., “scaffold free”). The choice of scaffold and cells ultimately depends on the goals of the therapy, so the review considers how congenital heart defects define the design parameters for cardiac tissue engineering needed for surgical repair in pediatric cardiac patients.


Cardiac tissue engineering Human cardiomyocytes Pluripotent stem cells Therapeutic biologic implant 


  1. 1.
    Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA, Druid H, Jovinge S, Frisen J (2009) Evidence for cardiomyocyte renewal in humans. Science 324:98–102PubMedCrossRefGoogle Scholar
  2. 2.
    Bian W, Liau B, Badie N, Bursac N (2009) Mesoscopic hydrogel molding to control the 3D geometry of bioartificial muscle tissues. Nat Protoc 4:1522–1534PubMedCrossRefGoogle Scholar
  3. 3.
    Carvajal-Vergara X, Sevilla A, D’Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, Ge Y, Cohen N, Edelmann LJ, Chang B, Waghray A, Su J, Pardo S, Lichtenbelt KD, Tartaglia M, Gelb BD, Lemischka IR (2010) Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465:808–812PubMedCrossRefGoogle Scholar
  4. 4.
    Caspi O, Lesman A, Basevitch Y, Gepstein A, Arbel G, Habib IH, Gepstein L, Levenberg S (2007) Tissue engineering of vascularized cardiac muscle from human embryonic stem cells. Circ Res 100:263–272PubMedCrossRefGoogle Scholar
  5. 5.
    Congenital Cardiovascular Defects–Statistics (ICD/10 Q20-Q28; ICD/9 745-747). Statistical Fact Sheet–Miscellaneous/Disease 2010 Update. American Heart Association, Dallas, TXGoogle Scholar
  6. 6.
    Dai W, Field LJ, Rubart M, Reuter S, Hale SL, Zweigerdt R, Graichen RE, Kay GL, Jyrala AJ, Colman A, Davidson BP, Pera M, Kloner RA (2007) Survival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts. J Mol Cell Cardiol 43:504–516PubMedCrossRefGoogle Scholar
  7. 7.
    Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142:375–386PubMedCrossRefGoogle Scholar
  8. 8.
    Kita-Matsuo H, Barcova M, Prigozhina N, Salomonis N, Wei K, Jacot JG, Nelson B, Spiering S, Haverslag R, Kim C, Talantova M, Bajpai R, Calzolari D, Terskikh A, McCulloch AD, Price JH, Conklin BR, Chen HS, Mercola M (2009) Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. PLoS One 4:e5046PubMedCrossRefGoogle Scholar
  9. 9.
    Kofidis T, Lebl DR, Swijnenburg RJ, Greeve JM, Klima U, Robbins RC (2006) Allopurinol/uricase and ibuprofen enhance engraftment of cardiomyocyte-enriched human embryonic stem cells and improve cardiac function following myocardial injury. Eur J Cardiothorac Surg 29:50–55PubMedCrossRefGoogle Scholar
  10. 10.
    Laflamme MA, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, O’Sullivan C, Collins L, Chen Y, Minami E, Gill EA, Ueno S, Yuan C, Gold J, Murry CE (2007) Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25:1015–1024PubMedCrossRefGoogle Scholar
  11. 11.
    Leor J, Gerecht S, Cohen S, Miller L, Holbova R, Ziskind A, Shachar M, Feinberg MS, Guetta E, Itskovitz-Eldor J (2007) Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart 93:1278–1284PubMedCrossRefGoogle Scholar
  12. 12.
    Lesman A, Habib M, Caspi O, Gepstein A, Arbel G, Levenberg S, Gepstein L (2010) Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng Part A 16:115–125PubMedCrossRefGoogle Scholar
  13. 13.
    Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, Plath K (2008) Generation of human-induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA 105:2883–2888PubMedCrossRefGoogle Scholar
  14. 14.
    Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate JA, Cuy JL, Hauch KD, Laflamme MA, Murry CE, Ratner BD (2010) Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc Natl Acad Sci USA 107:15211–15216PubMedCrossRefGoogle Scholar
  15. 15.
    Miyagawa S, Sawa Y, Sakakida S, Taketani S, Kondoh H, Memon IA, Imanishi Y, Shimizu T, Okano T, Matsuda H (2005) Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: their integration with recipient myocardium. Transplantation 80:1586–1595PubMedCrossRefGoogle Scholar
  16. 16.
    Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schomig A, Laugwitz KL (2010) Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363(15):1397–1409PubMedCrossRefGoogle Scholar
  17. 17.
    Naito H, Melnychenko I, Didie M, Schneiderbanger K, Schubert P, Rosenkranz S, Eschenhagen T, Zimmermann WH (2006) Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation 114:I72–I78PubMedCrossRefGoogle Scholar
  18. 18.
    Niebruegge S, Bauwens CL, Peerani R, Thavandiran N, Masse S, Sevaptisidis E, Nanthakumar K, Woodhouse K, Husain M, Kumacheva E, Zandstra PW (2009) Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol Bioeng 102:493–507PubMedCrossRefGoogle Scholar
  19. 19.
    Ott HC, Matthiesen TS, Goh SK, Black LD, Kren SM, Netoff TI, Taylor DA (2008) Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart. Nat Med 14:213–221PubMedCrossRefGoogle Scholar
  20. 20.
    Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451:141–146PubMedCrossRefGoogle Scholar
  21. 21.
    Radisic M, Park H, Shing H, Consi T, Schoen FJ, Langer R, Freed LE, Vunjak-Novakovic G (2004) Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc Natl Acad Sci USA 101:18129–18134PubMedCrossRefGoogle Scholar
  22. 22.
    Rust W, Balakrishnan T, Zweigerdt R (2009) Cardiomyocyte enrichment from human embryonic stem cell cultures by selection of ALCAM surface expression. Regen Med 4:225–237PubMedCrossRefGoogle Scholar
  23. 23.
    Shachar M, Tsur-Gang O, Dvir T, Leor J, Cohen S (2011) The effect of immobilized RGD peptide in alginate scaffolds on cardiac tissue engineering. Acta Biomater 7(1):152–162PubMedCrossRefGoogle Scholar
  24. 24.
    Shiba Y, Hauch KD, Laflamme MA (2009) Cardiac applications for human pluripotent stem cells. Curr Pharm Des 15:2791–2806PubMedCrossRefGoogle Scholar
  25. 25.
    Stevens KR, Kreutziger KL, Dupras SK, Korte FS, Regnier M, Muskheli V, Nourse MB, Bendixen K, Reinecke H, Murry CE (2009) Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci USA 106:16568–16573PubMedCrossRefGoogle Scholar
  26. 26.
    Stevens KR, Pabon L, Muskheli V, Murry CE (2009) Scaffold-free human cardiac tissue patch created from embryonic stem cells. Tissue Eng Part A 15:1211–1222PubMedCrossRefGoogle Scholar
  27. 27.
    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872PubMedCrossRefGoogle Scholar
  28. 28.
    Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA (2005) Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366:2019–2025PubMedCrossRefGoogle Scholar
  29. 29.
    Tulloch NL, Pabon L, Murry CE (2008) Get with the (re)program: cardiovascular potential of skin-derived induced pluripotent stem cells. Circulation 118:472–475PubMedCrossRefGoogle Scholar
  30. 30.
    van Laake LW, Passier R, Monshouwer-Kloots J, Verkleij AJ, Lips DJ, Freund C, den Ouden K, Ward-van Oostwaard D, Korving J, Tertoolen LG, van Echteld CJ, Doevendans PA, Mummery CL (2007) Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res 1:9–24PubMedCrossRefGoogle Scholar
  31. 31.
    Vunjak-Novakovic G, Tandon N, Godier A, Maidhof R, Marsano A, Martens TP, Radisic M (2010) Challenges in cardiac tissue engineering. Tissue Eng Part B Rev 16:169–187PubMedCrossRefGoogle Scholar
  32. 32.
    Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920PubMedCrossRefGoogle Scholar
  33. 33.
    Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ (2009) Functional cardiomyocytes derived from human-induced pluripotent stem cells. Circ Res 104:e30–e41PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang Y, Nuglozeh E, Toure F, Schmidt AM, Vunjak-Novakovic G (2009) Controllable expansion of primary cardiomyocytes by reversible immortalization. Hum Gene Ther 20:1687–1696PubMedCrossRefGoogle Scholar
  35. 35.
    Zhu WZ, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA (2010) Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res Published online 29 July. doi:10.1161/CIRCRESAHA.1110.223917
  36. 36.
    Zimmermann WH, Cesnjevar R (2009) Cardiac tissue engineering: implications for pediatric heart surgery. Pediatr Cardiol 30:716–723PubMedCrossRefGoogle Scholar
  37. 37.
    Zimmermann WH, Fink C, Kralisch D, Remmers U, Weil J, Eschenhagen T (2000) Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol Bioeng 68:106–114PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative MedicineUniversity of WashingtonSeattleUSA
  2. 2.Department of PathologyUniversity of WashingtonSeattleUSA
  3. 3.Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative MedicineUniversity of WashingtonSeattleUSA
  4. 4.Department of BioengineeringUniversity of WashingtonSeattleUSA
  5. 5.Department of Medicine/CardiologyUniversity of WashingtonSeattleUSA

Personalised recommendations